Want to join the conversation?
Barclays analyst Matthew Taylor questions $ABT on the contribution of new products in Medical Devices segment. CEO Miles White says that the Vascular business is doing better with MitraClip being a big contributor. On the core stent business, there is pricing pressure due to stiff competition, but that business is gaining share and doing well.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.